Success Metrics

Active Trials

3(60%)

Phase Distribution

Ph phase_1

60%

Ph phase_2

20%

Ph phase_4

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

1(20.0%)

Phase 4Post-market surveillance

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Other(1)

Detailed Status

Recruiting3

Not yet recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 4

Trials by Phase

Phase 13 (60.0%)

Phase 21 (20.0%)

Phase 41 (20.0%)

Trials by Status

not_yet_recruiting120%

recruiting360%

unknown120%

Recent Activity

3 active trials

Showing 5 of 5

recruitingphase_4

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

NCT05806580

recruitingphase_2

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

NCT06479356

recruitingphase_1

Clinical Trials (5)

Showing 5 of 5 trials

NCT05806580Phase 4

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Recruiting

NCT06479356Phase 2

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Recruiting

NCT06414135Phase 1

Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis

Recruiting

NCT06297408Phase 1

Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus

Not Yet Recruiting

NCT05765006Phase 1

CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus

Unknown

All 5 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 5